Technical, preclinical, and clinical developments of Fc-glycan-specific antibody–drug conjugates
2025

Advancements in Antibody-Drug Conjugates for Cancer Therapy

Sample size: 159 publication Evidence: moderate

Author Information

Author(s): Qiang Yang, Yunpeng Liu

Hypothesis

Fc-glycan-specific antibody-drug conjugates (gsADCs) can improve the efficacy and safety of cancer treatments.

Conclusion

Fc-glycan-specific ADCs show promising results in clinical trials, indicating their potential to enhance cancer therapy.

Supporting Evidence

  • JSKN003 and IBI343 have shown promising results in phase 1 trials.
  • IBI343 received fast-track designation by the FDA for pancreatic cancer treatment.
  • gsADCs have demonstrated comparable or superior efficacy to traditional ADCs in preclinical studies.

Takeaway

Scientists are making better cancer treatments by attaching drugs to antibodies in a special way that helps them work better and cause fewer side effects.

Methodology

The article reviews various glycan-specific conjugation techniques and discusses the development stages of several gsADCs.

Limitations

Increased manufacturing costs and potential challenges in large-scale production of gsADCs.

Participant Demographics

Patients with advanced gastric/gastroesophageal junction adenocarcinoma and other solid tumors.

Digital Object Identifier (DOI)

10.1039/d4md00637b

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication